Colorectal Cancer Liver Metastases: Neoadjuvant Therapy with Bevacizumab
Metastatic colorectal cancer (mCRC) is still thought to be a disease resulting in early death in most cases, and patients are depressed by the diagnosis and its dismal prognosis described to them by their physicians. Multidisciplinary teams have, however, considerably changed the survival options, and the combination of effective chemotherapy plus targeted agents and surgery are nowadays lead ing to the potential cure for some mCRC patients. This highly specialized approach to the treatment of mCRC needs to be dis tributed to patients, physicians and health care providers to maximize the potential benefit (Gruenberger et al., 2004).
Advances in the outcome of mCRC patients have been achieved by both medi cal and surgical oncologists, but the most important step was the combination of the knowledge of these specialists in tumor treatment boards where experienced radiologist and radiation therapists were included in a structured algorithm to treat mCRC patients.
KeywordsOncol Diarrhea Neutropenia Peri Bevacizumab
Unable to display preview. Download preview PDF.
- Aloia, T., Sebagh, M., Plasse, M., Karam, V., Levi, F., Giacchetti, S., Azoulay, D., Bismuth, H., Castaing, D., and Adam, R. 2006. Liver histol ogy and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol. 24: 4983–4990.PubMedCrossRefGoogle Scholar
- Gruenberger, T., Tamandl, D., Puhalla, H., Scheithauer, W., Zielinski, C., and Gruenberger, B. 2007. Bevacizumab plus XELOX as neo-adjuvant therapy for patients with poten tially curable metastatic colorectal cancer. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25, 18 S (June 20 Supplement): 4064.Google Scholar
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. 2004. Bevacizumab plus irinotecan, fluorou-racil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350: 2335–2342.PubMedCrossRefGoogle Scholar
- Kesmodel, S., Ellis, L., Lin, E., Chang, G., Abdalla, E., Kopetz, S., Vauthey, J., Rodrigues-Bigas, M., Curley, S., and Feig, B. 2007. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. ASCO GI meet ing abstract. Abstract 234.Google Scholar
- Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A. D., Brezault, C., Le Charpentier, M., Dousset, B., Morel, P., Soubrane, O., Chaussade, S., Mentha, G., and Terris, B. 2004. Severe hepatic sinusoi dal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorec-tal cancer. Ann. Oncol. 15: 460–466.CrossRefGoogle Scholar
- Saltz, L., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitzer, M., Yang, T., and Cassidy, J. 2007a. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treat ment of metastatic colorectal cancer (MCRC). ASCO GI meeting abstract. Abstract 238.Google Scholar
- Saltz, L., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitzer, M., Yang, T., and Cassidy, J. 2007b. Updated efficacy results from XELOX-1/NO16966, a randomised phase III trial in first-line metastatic colorectal cancer: analysis of bevacizumab in combination with XELOX or FOLFOX-4. Ann. Oncol. 18(Suppl.7): vii21 (abstract O-0032).Google Scholar